





Precision today, access tomorrow.

Why TAVI practitioners are switching to the ACURATE *neo2* Valve:

 $\langle \mathbf{0} \mathbf{\cdot} \rangle$

 \bigcirc

From routine, to challenging.

A valve as versatile as your cases.

Uniquely designed with an **open-frame** and **supra-annular leaflets**, the ACURATE *neo2*[™] Valve delivers the performance you expect today, without restricting the access you demand tomorrow.¹

The ACURATE *neo2* Aortic Valve System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.



 Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent (RE-ACCESS); NCT04026204. J Am. Coll. Cardiol. Intv. 2020.

Trusted outcomes.

- Best-in-class PPi
- Single-digit gradients
- Advanced PVL performance

Unrestricted design.

- Unrestricted coronary access
- Long-term hemodynamics
- Engineered to last

Precise procedures.

- Smooth deliverability
- Predictable alignment
- Accurate positioning



Hybrid benefits deliver the "best of both".

The first of its kind, ACURATE *neo2* is the only valve designed to offer the best benefits of both supraand intra- valve platforms.

Open-frame design

Provides unrestricted access for future interventions

Supra-annular leaflets

Achieves large EOAs and single-digit gradients¹

60% larger^{*} sealing skirt conforms to the native aortic annulus

Accurate positioning

Upper- and lower-crown anchoring provides first-time, precise procedures

*Next-generation ACURATE neo2 Valve vs. ACURATE neo™ Valve 1. Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 Valve System for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol. 2021;110:1912–1920. NA



Best-in-class PPi.

Lower your patients' risk of needing a pacemaker. With top-down deployment and upper- and lower-crown anchoring, ACURATE *neo2* minimizes LVOT protrusion to:1

Reduce the risk of new conduction disturbances

Reduce patient length of stay



ACURATE neo2 permanent pacemaker rate among pacemaker-naïve patients at 30 days in the PMCF study: 6.5% ²

- 1. Early neo2 Registry. Full Core-Lab Results of TAVI with the New ACURATE neo2 Valve. TVT Congress, Presenter: Andreas Rück, July 20, 2021.
- 2. Kim W., et al: Clinical outcomes of the ACURATE *neo2* transcatheter heart value; a prospective. multicenter, observational, post-market surveillance study, EuroIntervention 2022. DOI: 10.4244/ EIJ-D-22-00914







Single-digit gradients.

Protect your patient's future. Minimize the risk of patient-prosthesis mismatch, even in patients with small annuli.

cm²

See the evidence.

EOAs¹



mmHg

Supra-annular leaflets help you deliver **large EOAs** and **low mean** gradients.

2.9%


severe prosthesis-

patient mismatch – compared to 15% (P < 0.001) for SAPIEN 3 Ultra³



Advanced PVL performance.

Protect against PVL with the ACURATE *neo2* Valve's advanced sealing skirt:



ACURATE neo2 mean aortic gradients at 30 days in the PMCF study: 8.6mmHg. ACURATE neo2 mean effective orifice area at 30 days in the PMCF study: 1.6 sq. cm³

8.0

gradients²

- Möllmann H, Holzhey DM, Hilker M, et al. The ACURATE neo2 Valve System for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol. 2021;110:1912–1920.
- 2. Early neo2 Registry. Full Core-Lab Results of TAVI with the New ACURATE neo2 Valve. TVT Congress. Presenter: Andreas Rück. July 20, 2021.
- 3. Kim W., et al; Clinical outcomes of the ACURATE neo2 transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, EuroIntervention 2022. DOI: 10.4244/EIJ-D-22-00914

* At 30-days, Echocardiographic and CT imaging independently core lab adjudicated

 Kim W., et al; Clinical outcomes of the ACURATE *neo2* transcatheter heart valve: a prospective, multicenter, observational, post-market surveillance study, EuroIntervention 2022. DOI: 10.4244/EU-D-22-00914



Active PVseal[™] conforms to native valve annulus







Unrestricted coronary access.

Lower-risk TAVI requires preserved future access.¹ STEMI following TAVI resulted in:

4x higher PCI failure rate

33% increased mortality rate²

100%	82 [%]	99 %
ACURATE <i>neo</i> ™ Valve platform	Evolut™ R/PRO	SAPIEN
100% successful coronary cannulation n = 72	82% successful coronary cannulation n = 123	99% successful coronary cannulation n = 96

1. Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent (RE ACCESS); NCT04026204. J Am Coll Cardiol Intv. 2020.

2. Faroux L, et al. ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. "https://www.jacc.org/journal/jacc" J Am. Coll. Cardiol. 2021 May, 77 (17) 2187 -2199.





Long-term hemodynamic function.¹

Reduce the risk of valve deterioration and improve long-term cardiac function with a self-expanding, supra-annular design.²

Excellent durability.³

Supra-annular leaflets treated with BioFix[™] anti-calcification process are designed with your patient's lifetime in mind.⁴

Accelerated wear testing equivalent to 25 years demonstrated robust wear resistance and excellent hydrodynamic performance³

1. Sigueira DA, Simonato M, Ramos AA, et al. Mid- to long-term clinical and echocardiographic outcomes after transcatheter aortic valve replacement with a new-generation, self-expandable system. Catheter Cardiovasc Interv. 2021.

2. Flameng, W, et al. Prosthesis-Patient Mismatch Predicts Structural Valve Degeneration in Bioprosthetic Heart Valves. Circulation. 2010; 121:2123-2129. 3. Sathanathan et al., Long-Term Durability of the Next-Generation Acurate neo 2, Am. Coll. Cardiol. Intv. 2020 JACC, Vol. 14, NO. 5, 2021 MARCH 8, 2021:583 –92. 4. Anderson-Cunanan C et al, Calcification Assessment of the BSC-Symetis Valve Leaflet Material Treated with the BiofixTM Process

Am, Coll, Cardiol, Intv. 2019, JACC CI, Vol. 12, NO. 4, 2019 FEB 2019, 535 –936.









Smooth deliverability.

Expect uncompromised deliverability even in small and tortuous anatomies with low-profile iSLEEVE[™]* Expandable Introducer Sheath and intuitive, top-down deployment with the ACURATE *neo2*[™] Valve.

Superior device success among patients with horizontal aortas:

91.2[%] vs. 86.6[%] ACURATE neo21 (P < 0.002)

* The iSLEEVE Expandable Introducer Sheath is indicated for vessels ≥ 5.5mm.

1. Gallo F, Gallone G, Kim W-K, et al. Horizontal aorta in transcatheter self-expanding valves: Insights from the HORSE International Multicentre Registry. Circ Cardiovasc Interv. 2021;14(9):e010641.





Predictable alignment.

ACURATE *neo2*[™] was the only valve to **100%** avoid moderate or severe commissural misalignment.¹

Precise positioning.

Easy-to-spot radiopaque positioning marker ensures enhanced visualization for delivering short procedures and high success rates.²




98.4[%]

procedural success³

1. Bieliauskas G, Wong I, Bajoras V, et al. Patient-specific implantation technique to obtain neocommissural alignment with self-expanding transcatheter aortic valves. JACC Cardiovasc Interv. 2021:14(19):2097-2108.

- 2. Möllmann H. Holzhey DM, Hilker M, et al. The ACURATE neo2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. Clin Res Cardiol. 2021;110(12):1912–1920.
- 3. Kim W., et al: Clinical outcomes of the ACURATE *neo2* transcatheter heart valve; a prospective. multicenter, observational, post-market surveillance study, EuroIntervention 2022. DOI: 10.4244/ EIJ-D-22-00914







Ordering Information

Ref/Catalog Number	Description	Units
ACURATE neo2 Aortic Valves		
SYM-SV23-004	ACURATE neo2 Aortic Valve S	1
SYM-SV25-004	ACURATE neo2 Aortic Valve M	1
SYM-SV27-004	ACURATE neo2 Aortic Valve L	1
ACURATE neo2 Transfemoral Delivery System and Loading Kit		

ACURATE neo2 Transfemoral Delivery System

ACURATE neo2 Loading Kit



ACURATE neo2 Aortic Valve Generic Bundle Codes

BUN67NEO2DSTF	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit
BUN67NEO2DSTFIS14	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLEEVE
BUN67NEO2IS14SAF	Generic Bundle ACURATE neo2 Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLEEVE + SAFARI2
BUN67NEO2ISSAFSEN	Generic Bundle ACURATE <i>neo2</i> Aortic Valve + Transfemoral Delivery System + Loading Kit + 14F iSLEEVE + SAFARI ² + SENTINEL [™]

All trademarks are property of their respective owner. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Information not for use or distribution in France. Illustrations for information purposes – not indicative of actual size or clinical outcome. All photographs taken by Boston Scientific.



© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.

SH-809013-AE

SYM-DS-010

SYM-AC-010

